Press

atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer

Dec 13 • 3 min read

atai Life Sciences N.V., (NASDAQ: ATAI), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced today its appointment of Dr. Kirpekar to serve as the Company’s Chief Business Officer, effective today. In this newly created role, Dr. Kirpekar will be responsible for atai’s pipeline strategy, building out its commercial…

PanGenomic Health Completes Acquisition of Mindleap Health

Dec 12 • 4 min read

PanGenomic Health Inc. CSE: NARA, is pleased to announce, further to its news releases dated September 1, 2022 and November 21, 2022, the completion of its previously announced acquisition (the “Transaction”) of Mindleap Health Inc. from Mydecine Innovations Group Inc., a company listed on the NEO Exchange. “We are excited about the acquisition of Mindleap as it represents…

Lusaris Therapeutics Launches with $60 Million Series A Financing to Redefine the Treatment of Severe Neuropsychiatric and Neurological Disorders

Dec 9 • 4 min read

Lusaris Therapeutics, a biotechnology company advancing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological conditions, launched today with a $60 million Series A financing. The company’s lead program, LSR-1019, is a best-in-class sublingual formulation of 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a fast-acting and rapidly clearing serotonergic psychedelic, in development for patients with treatment-resistant depression (TRD) and…

Sensorium Therapeutics Closes $30 Million Series A to Transform Mental Health Treatment with Nature-Inspired Psychoactive Medicines

Dec 9 • 4 min read

Sensorium Therapeutics, a biotechnology company leveraging medicinal chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health, today announced the closing of a $30 million Series A financing to advance its initial asset, SENS-01, and Biodynamic Discovery PlatformTM (BDP), a drug discovery engine that rapidly identifies, synthesizes, and enhances targeted molecules as novel…

Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute

Dec 9 • 2 min read

Clearmind Medicine Inc. (Nasdaq: CMND | CSE: CMND | FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the appointment of seasoned regulatory executive Nicholas Kadysh as special advisor for the development of MEAI as an alcohol substitute. Kadysh, a former executive…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441